Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen[…]
Pemetrexed (Alimta)
The Effectiveness of Cisplatin and Pemetrexed in Pericardial Mesothelioma
Out of all the types of mesothelioma, pericardial mesothelioma is one of the rarest forms, accounting for only 0.002% of all known diagnosed mesothelioma cases. Mesothelioma is caused by asbestos exposure, and despite this knowledge and years of research, scientists and researchers still do not have a clear answer as[…]
Determining and Prolonging Survival Rates In Mesothelioma
The average survival rate for mesothelioma after diagnosis is less than one year; however, certain individuals will survive longer than others, but the reason as to why this is, is largely unknown. The latest study to be published in Histopathology investigates what it is in the body that determines a[…]
Mesothelioma Treatments Used Alongside Surgery – A Clinical Trial
Rare and aggressive in nature, mesothelioma is often a fatal cancer mainly due to its lack of response to most treatments. Surgical options have a higher chance of success for those in the early stages of the disease, but since there is a long latency period between asbestos exposure and[…]
Improvements in Radiation Therapies Give More Treatment Options
When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin and pemetrexed are first line treatments, especially among those who do not quality for surgery. Radiation treatment is available, but[…]
Giving Cediranib Another Chance
A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial[…]
Pembrolizumab Update: Aduro Biotech Collaborates with Merck
A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYTRUDA ® treatment began to circulate late last year when data presented at the[…]
Bevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients
The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to[…]
The Latest Clinical Trial for Nintedanib – Are You a Candidate?
Scientists and researchers are excited over the latest completion of a Phase II clinical trial for those suffering from mesothelioma – an incurable asbestos-caused cancer that has a median survival of only 9 to 12 months. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma showed a slight[…]
Ptac2S Potentially More Effective Than Cisplatin When Fighting Mesothelioma
Malignant Pleural Mesothelioma (MPM) is a rare, aggressive asbestos –related cancer that has a poor survival rate due to the fact that the cancer is hard to detect early, and once detected, has usually spread and is hard to control. Surgery is typically an effective option for removing cancerous cells,[…]
